Cannabis After Schedule III

Cannabis tax planning is entering a new phase as the rescheduling of certain medical cannabis products to Schedule III changes the federal tax considerations facing eligible businesses. In this episode of Let’s Talk Tax, host Dave McGuire sits down with David Seibel, EA, to discuss what the change could mean for Section 280E, potential tax credits, and business investment decisions.

The conversation explores how the treatment of eligible medical cannabis operations may affect deductions and federal tax credits, including potential research and development activities involving cultivation consistency, product formulations, purity, and process improvements. Dave and David also discuss bonus depreciation and qualified production property, along with the conditions businesses must evaluate before pursuing these opportunities.

For CPAs and business advisors, the distinction between medical and recreational operations is especially important. The discussion covers expense allocation, business licenses, entity structures, recordkeeping, and the need to prepare for additional IRS and Treasury guidance. State tax rules can also create different outcomes, making it important to evaluate each client’s circumstances rather than assume federal changes apply uniformly.

Listen to the full episode of Let’s Talk Tax to learn what cannabis businesses and their advisors should consider as they evaluate tax planning opportunities, documentation needs, and the evolving regulatory landscape.